KOL Pulse exists because oncology intelligence should be transparent, audited, and accessible — not gated behind six-figure SaaS contracts. Every page on this site, every trial profile, every conference recap is built and shipped by a single founder using AI tooling end-to-end.
As a veteran of the biotech and pharmaceutical industry, I invented KOL Pulse to provide transparency and accessibility of KOL sentiment data to the healthcare community. Two stories explain how I got here — a $67 million whistleblower case I filed against my own employer, and the phone call that came in the middle of the professional fallout from it.
Before I built KOL Pulse, I was a product manager and sales representative at Genentech for an oral lung-cancer drug called Tarceva (erlotinib). It was an exciting period in oncology. Targeted therapies were finally arriving, and EGFR-mutation testing was emerging as the way to identify which patients would actually benefit from drugs like ours.
The signal in the data was clean once you looked carefully: Tarceva meaningfully extended survival in EGFR-mutated NSCLC and only EGFR-mutated NSCLC. There was an early appearance of "never-smoker benefit" floating in the marketing materials, but that was a surrogate — a false signal driven by population overlap. Never-smokers carry EGFR mutations at much higher rates than smokers, so a survival bump in never-smokers was really an EGFR-mutation bump wearing a smoking-status disguise. Stratify by EGFR status and the smoking signal disappears.
What I watched happen inside the company is what eventually drove me to act. The marketing strategy promoted Tarceva broadly across the entire FDA-approved indication, with sales materials emphasizing survival data drawn from favorable subgroups, including the never-smoker surrogate. Physicians were actively discouraged from ordering EGFR mutation testing.
In 2010, I raised these concerns directly inside a Tarceva marketing meeting. My supervisor's response was that I "was not a team player."
I filed a qui tam whistleblower complaint on February 22, 2011 in the Northern District of California. The Department of Justice intervened. After five years of litigation, Genentech and OSI Pharmaceuticals agreed to pay $67 million to settle the False Claims Act allegations — at the time the largest pharmaceutical recovery involving misleading survival-data claims.
The case was never about a single bad drug. It was about an information asymmetry — a gap between what the most informed clinicians actually knew and what community physicians and patients were being told. The same gap I'd later watch the social KOLs work to close, in real time, on Twitter.
Filing a False Claims Act case against your employer is not a quiet career move. The complaint was filed under seal — qui tam cases stay sealed while the Department of Justice investigates, sometimes for years — so I couldn't talk about any of it. Publicly, I was just in a tough job transition. Privately, I was carrying the case alone. My stress level and anxiety were very high. I was very much consumed with my current situation, how I was going to support my family, and the interpersonal stress that accompanies that kind of transition.
During that time — while the case was still under seal — I made a visit to West Point, my Alma Mater, for a reunion event. I was sitting at the bar of the Thayer Hotel talking to the general who led our forces in Afghanistan. Mid-conversation, a friend called me with news that changed my life. She told me she had been diagnosed with lung cancer, and the cancer had begun to spread after her initial cycles of chemo. She was still in very good shape, but based on her scans, her prognosis was grim.
I had been working in the lung cancer world for a while — as a sales rep in Miami and as a marketer in South San Francisco. As a sales rep, I'd had thousands of conversations with lung cancer clinicians and oncology staff. I had learned how frightening and how quickly this disease strikes.
My experience gave me a unique perspective. I had spent hours in hotel conference rooms listening to the top Key Opinion Leaders discuss new therapies and treatment strategies. I understood — as the Tarceva case had only sharpened — that KOLs were years ahead of the FDA and community-based guidelines that supported the majority of cancer patients.
Intent on helping my friend, I gave her a list of KOL names. The clock was ticking, but she was determined to live. She hustled to cancer centers around the nation. She looked each KOL in the eyes and asked pointed questions. She was offered several clinical trial opportunities. She picked her KOL and chose the trial she thought was best for her.
She became patient 21, if I recall correctly, on a new drug called Keytruda. Today she is healthy and still out there hustling. She is a superstar. — And KOLs saved her life.
In that moment, I saw KOLs in a new light. They are amazing — but I am especially amazed by the social KOLs and their communication skills. They take conversations once isolated to hotel conference rooms and put them out there for the greater benefit of all.
My friend got Keytruda because I happened to know the right KOLs to call. The Tarceva case happened because internal data didn't reach the prescribers and patients who needed it. Both come down to the same problem: the fastest, most rigorous oncology thinking lives in the heads of a few hundred KOLs, and most of the healthcare ecosystem doesn't have direct access to it.
With AI and curation tools, KOL Pulse captures the clinical-trial opinions of the most active and influential oncology KOLs on social media and curates that content into easy-to-read synopses with sentiment and backing commentary. We deliver remarkably accurate summaries in record time. We cover every major oncology conference in the U.S. and publish KOL summaries of clinical-trial results within hours of the original posts.
KOL Pulse isn't a 50-person SaaS company with a deck full of headcount and a per-seat price list. It's an AI-native operation: I run the curation pipelines, write the prompts, deploy the pages, and ship the intelligence. AI does the heavy lifting on tweet collection, sentiment classification, OCR of conference slides, KOL deduplication, and HTML generation. I handle the judgment calls.
The other half of "AI-native" is what most websites still ignore: every page on this site is also designed to be consumed by AI. Each trial profile, conference recap, and KOL page is effectively a structured database — verbatim KOL tweets with handles and dates, OCR'd conference slides, Open Payments figures, sentiment classifications, source links — laid out so it can be dropped straight into NotebookLM, Claude, ChatGPT, Perplexity, or whatever tool comes next as ready-to-use context. Med-affairs and commercial teams aren't just reading these pages anymore; they're feeding them to their own AI workflows.
KOL Pulse is for professionals across the biotech and pharmaceutical ecosystem. Whether your job is compiling KOL sentiment or consuming it, the mission is the same: quick and reliable access to data that used to be locked inside hotel conference rooms.
See what your peers and the leading voices in your indication are actually saying about pivotal trial data — sentiment, conflicts, and consensus.
Track real-time KOL reaction to your assets and competitors at every major oncology congress, with full source transparency.
Skip weeks of manual social listening. KOL Pulse delivers ready-to-use sentiment dashboards within hours of plenary readouts.
Identify the KOLs who are shaping practice on social — including the rising voices your traditional KOL maps don't capture.
Book a 30-minute walkthrough of trial profiles, conference coverage, and the KOL leaderboards your med-affairs and commercial teams should be watching.